{"id":18317,"date":"2025-07-25T10:13:16","date_gmt":"2025-07-25T10:13:16","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=18317"},"modified":"2025-07-25T10:13:16","modified_gmt":"2025-07-25T10:13:16","slug":"medicinova-shares-update-on-als-triglyceride-trials","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","title":{"rendered":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8a66\u9a13\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u306f\u3001\u30ca\u30b9\u30c0\u30c3\u30af\u30fb\u30b0\u30ed\u30fc\u30d0\u30eb\u30fb\u30de\u30fc\u30b1\u30c3\u30c8\u304a\u3088\u3073\u7c73\u56fd\u9023\u90a6\u8a3c\u5238\u53d6\u5f15\u6240\uff08NASDAQ\uff09\u3067\u53d6\u5f15\u3055\u308c\u3066\u3044\u308b\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f1a\u793e\u3067\u3059\u3002 <a href=\"https:\/\/www.jpx.co.jp\/\" data-no-translation=\"\">Standard Market of the Tokyo Stock Exchange<\/a>, provides an update on the enrollment of two key ongoing clinical trials for the Company&rsquo;s developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast), each of which is poised to complete randomization.<\/p><p>\u5177\u4f53\u7684\u306b\u306f\u3001\u73fe\u5728\u9032\u884c\u4e2d\u306e\u30d5\u30a7\u30fc\u30ba2\/3\u8a66\u9a13\u3067\u3042\u308b COMBAT-ALS \u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u7121\u4f5c\u70ba\u5316\u304c\u5fc5\u8981\u306a\u88ab\u9a13\u8005\u6570\u304c\u4e00\u6841\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u540c\u6642\u306b\u30012\u578b\u7cd6\u5c3f\u75c5\u306b\u3088\u308b\u8102\u8cea\u7570\u5e38\u75c7\u304a\u3088\u3073\u8102\u80aa\u6027\u809d\u75be\u60a3\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u6700\u5f8c\u306e\u7121\u4f5c\u70ba\u5316\u88ab\u9a13\u80052\u540d\u3092\u52df\u96c6\u3057\u3066\u3044\u307e\u3059\u3002<\/p><h4>MN-166\uff08\u30a4\u30d6\u30b8\u30e9\u30b9\u30c8\uff09\u306b\u3064\u3044\u3066<\/h4><p>MN-166\uff08\u30a4\u30d6\u30b8\u30e9\u30b9\u30c8\uff09\u306f\u3001\u30db\u30b9\u30db\u30b8\u30a8\u30b9\u30c6\u30e9\u30fc\u30bc4\u578b\uff08PDE4\uff09\u3068\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u904a\u8d70\u963b\u6b62\u56e0\u5b50\uff08MIF\uff09\u3092\u542b\u3080\u708e\u75c7\u6027\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u3092\u963b\u5bb3\u3059\u308b\u7d4c\u53e3\u6295\u4e0e\u53ef\u80fd\u306a\u4f4e\u5206\u5b50\u5316\u5408\u7269\u3067\u3059\u3002\u7b4b\u840e\u7e2e\u6027\u5074\u7d22\u786c\u5316\u75c7\uff08ALS\uff09\u3001\u9032\u884c\u6027\u591a\u767a\u6027\u786c\u5316\u75c7\uff08MS\uff09\u3001\u5909\u6027\u6027\u981a\u9ac4\u75c7\uff08DCM\uff09\u306a\u3069\u306e\u795e\u7d4c\u5909\u6027\u75be\u60a3\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u5f8c\u671f\u81e8\u5e8a\u958b\u767a\u6bb5\u968e\u306b\u3042\u308a\u3001\u81a0\u82bd\u816b\u3001\u30ed\u30f3\u30b0COVID\u3001\u5316\u5b66\u7642\u6cd5\u8a98\u767a\u6027\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\uff08CIPN\uff09\u3001\u85ac\u7269\u4f7f\u7528\u969c\u5bb3\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3082\u958b\u767a\u4e2d\u3067\u3059\u3002\u3055\u3089\u306b\u3001MN-166\u306f\u3001\u6025\u6027\u547c\u5438\u7aae\u8feb\u75c7\u5019\u7fa4\uff08ARDS\uff09\u3092\u767a\u75c7\u3059\u308b\u30ea\u30b9\u30af\u306e\u3042\u308b\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u8a55\u4fa1\u3055\u308c\u307e\u3057\u305f\u3002 <a href=\"https:\/\/medicinova.com\/\" data-no-translation=\"\">MediciNova<\/a> MN-166\u3001ALS\u6cbb\u7642\u85ac\u3068\u3057\u3066\u7c73\u56fdFDA\u304a\u3088\u3073\u6b27\u5ddeEMA\u3088\u308a\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d6\u5f97MN-166\u306f\u3001ALS\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066FDA\u3088\u308a\u30d5\u30a1\u30b9\u30c8\u30fb\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001MN-166\u306f\u81a0\u82bd\u816b\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306b\u6307\u5b9a\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p><h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/curadh-alpha-fusion-advance-astatine-211-collaboration\/\" rel=\"bookmark\">\u30ad\u30e5\u30e9\u30fc\u30ba\u3068\u30a2\u30eb\u30d5\u30a1\u30fb\u30d5\u30e5\u30fc\u30b8\u30e7\u30f3\u793e\u3001\u30a2\u30b9\u30bf\u30c1\u30f3-211\u306e\u5171\u540c\u7814\u7a76\u3092\u63a8\u9032<\/a><\/h4><h4>MN-001\uff08\u30c1\u30da\u30eb\u30ab\u30b9\u30c8\uff09\u306b\u3064\u3044\u3066<\/h4><p>MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO\/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001&rsquo;s inhibitory effect on 5-LO and the 5-LO\/LT pathway is a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, MN-001 was found to inhibit triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake.<\/p><p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/24\/3120842\/7767\/en\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.html\" data-no-translation=\"\">GlobeNewsWire<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange, provides an update on the enrollment of two key ongoing clinical trials for the Company&rsquo;s developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast), each of which is poised to complete randomization.Specifically, the Company is now down to single digit required randomization in its ongoing Phase 2\/3 COMBAT-ALS trial. Concurrently, the Company is seeking the final two randomized subjects for its Phase 2 trial in patients with dyslipidemia and fatty liver disease due to type 2 diabetes.About MN-166 (ibudilast)MN-166 (ibudilast) is an orally available small molecule compound that inhibits phosphodiesterase type-4 (PDE4) [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":18318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[6546,6547,6545,6548,424,6544],"ppma_author":[205],"class_list":["post-18317","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-health-tech","category-japan","category-news","category-pharma","category-regional","tag-clinical-trial","tag-hypertriglyceridemia","tag-ibudilast","tag-medicinova","tag-pharma","tag-tipelukast"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MediciNova Reports Progress on ALS and Lipid Trials<\/title>\n<meta name=\"description\" content=\"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediciNova Reports Progress on ALS and Lipid Trials\" \/>\n<meta property=\"og:description\" content=\"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T10:13:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u8102\u8cea\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u9032\u6357\u3092\u5831\u544a","description":"MediciNova\u793e\u306f\u3001MN-166\u3068MN-001\u306e\u8a66\u9a13\u306e\u767b\u9332\u9032\u6357\u72b6\u6cc1\u3092\u5171\u6709\u3057\u3001\u4e21\u8a66\u9a13\u3068\u3082\u7121\u4f5c\u70ba\u5316\u6bb5\u968e\u306e\u5b8c\u4e86\u306b\u8fd1\u3065\u3044\u3066\u3044\u307e\u3059\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","og_locale":"ja_JP","og_type":"article","og_title":"MediciNova Reports Progress on ALS and Lipid Trials","og_description":"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","og_site_name":"itbusinesstoday","article_published_time":"2025-07-25T10:13:16+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"MediciNova Shares Update on ALS, Triglyceride Trials","datePublished":"2025-07-25T10:13:16+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"},"wordCount":370,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","keywords":["clinical trial","Hypertriglyceridemia","ibudilast","MediciNova","Pharma","tipelukast"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","name":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u8102\u8cea\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u9032\u6357\u3092\u5831\u544a","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","datePublished":"2025-07-25T10:13:16+00:00","description":"MediciNova\u793e\u306f\u3001MN-166\u3068MN-001\u306e\u8a66\u9a13\u306e\u767b\u9332\u9032\u6357\u72b6\u6cc1\u3092\u5171\u6709\u3057\u3001\u4e21\u8a66\u9a13\u3068\u3082\u7121\u4f5c\u70ba\u5316\u6bb5\u968e\u306e\u5b8c\u4e86\u306b\u8fd1\u3065\u3044\u3066\u3044\u307e\u3059\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","width":1200,"height":800,"caption":"MediciNova"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"MediciNova Shares Update on ALS, Triglyceride Trials"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=18317"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317\/revisions"}],"predecessor-version":[{"id":18319,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317\/revisions\/18319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/18318"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=18317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=18317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=18317"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=18317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}